Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 amp ERBB2 over exp lung non-small cell carcinoma predicted - sensitive Ado-trastuzumab emtansine Case Reports/Case Series Actionable In a Phase II trial, a non-small cell lung cancer patient with ERBB2 overexpression (IHC 3+) and ERBB2 amplification demonstrated a partial response when treated with Kadcyla (ado-trastuzumab emtansine), with a duration of response of 8.3 months, a progression-free survival of 9.6 months, and an overall survival of 21.6 months (PMID: 30206164; NCT02289833). 30206164
ERBB2 amp ERBB2 over exp stomach cancer sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997). 23578997
ERBB2 amp ERBB2 over exp stomach cancer sensitive Ado-trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915). 21458915
ERBB2 amp ERBB2 over exp ERBB2 rearrange lung non-small cell carcinoma predicted - sensitive Ado-trastuzumab emtansine Case Reports/Case Series Actionable In a Phase II trial, a non-small cell lung cancer patient with ERBB2 overexpression (IHC 3+), ERBB2 amplification, and an ERBB2 rearrangement demonstrated a partial response when treated with Kadcyla (ado-trastuzumab emtansine), with a duration of response of 10.8 months, a progression-free survival of 12.2 months, and an overall survival of 12.9 months (PMID: 30206164; NCT02289833). 30206164
ERBB2 G776_V777insVC ERBB2 over exp lung non-small cell carcinoma predicted - sensitive Ado-trastuzumab emtansine Case Reports/Case Series Actionable In a Phase II trial, a non-small cell lung cancer patient with ERBB2 overexpression (IHC 3+) and harboring ERBB2 G776_V777insVC demonstrated a partial response when treated with Kadcyla (ado-trastuzumab emtansine), with a duration of response of 7.3 months, a progression-free survival of 8.5 months, and an overall survival of 20.2 months (PMID: 30206164; NCT02289833). 30206164
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Pertuzumab + Trastuzumab Preclinical Actionable In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Lapatinib + Trastuzumab Preclinical Actionable In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R stomach cancer predicted - resistant Trastuzumab Clinical Study - Cohort Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive Buparlisib + Pertuzumab + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive Buparlisib + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive Bevacizumab + Buparlisib Preclinical Actionable In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer no benefit Buparlisib + Lapatinib + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R SRC over exp urinary bladder cancer no benefit Ponatinib Preclinical - Pdx Actionable In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481). 26270481
ERBB2 over exp PIK3CA H1047R SRC over exp urinary bladder cancer no benefit Lapatinib Preclinical - Pdx Actionable In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481). 26270481
ERBB2 over exp PIK3CA mut Her2-receptor positive breast cancer sensitive PKI-179 Preclinical - Cell line xenograft Actionable In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855). 20797855
ERBB2 over exp PIK3CA mut breast cancer sensitive Miransertib + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). 26469692
ERBB2 over exp PIK3CA mut breast cancer sensitive Miransertib + Paclitaxel Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of Miransertib (ARQ092) and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). 26469692
ERBB2 over exp PIK3CA N345T stomach cancer predicted - resistant Trastuzumab Clinical Study - Cohort Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA H1047L stomach cancer predicted - resistant Trastuzumab Clinical Study - Cohort Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA act mut Her2-receptor positive breast cancer decreased response Poziotinib Phase II Actionable In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689). 30720867
ERBB2 over exp PIK3CA E542X Her2-receptor positive breast cancer decreased response Poziotinib Phase II Actionable In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689). 30720867
ERBB2 over exp PIK3CA E545X Her2-receptor positive breast cancer decreased response Poziotinib Phase II Actionable In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689). 30720867
ERBB2 over exp PIK3CA H1047X Her2-receptor positive breast cancer decreased response Poziotinib Phase II Actionable In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689). 30720867
Clinical Trial Phase Therapies Title Recruitment Status
NCT04209465 Phase I BDTX-189 A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Recruiting
NCT03734029 Phase III Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Recruiting
NCT04243616 Phase II Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer Recruiting
NCT01522768 Phase II Afatinib + Paclitaxel Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Active, not recruiting
NCT03587740 Phase II Ado-trastuzumab emtansine ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer Recruiting
NCT03505710 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Recruiting
NCT02605486 Phase Ib/II Bicalutamide + Palbociclib Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Recruiting
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed
NCT00968968 Phase III Trastuzumab Lapatinib + Trastuzumab Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Terminated
NCT03716180 Phase I Paclitaxel + Pertuzumab + Trastuzumab DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Active, not recruiting
NCT03135171 Phase I Pertuzumab + Tocilizumab + Trastuzumab Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab Recruiting
NCT02726399 Phase II Capecitabine + Cisplatin Ramucirumab + Trastuzumab Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer Terminated
NCT01466972 Phase II Pazopanib Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Completed
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting
NCT03417544 Phase II Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Active, not recruiting
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting
NCT02213042 Phase II Lapatinib + Trastuzumab Trastuzumab Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Completed
NCT01989676 Phase III Paclitaxel + Trastuzumab Paclitaxel + Trazimera A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Completed
NCT02025192 Phase I Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Completed
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Active, not recruiting
NCT03523585 Phase III Trastuzumab deruxtecan Capecitabine + Lapatinib Capecitabine + Trastuzumab DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Recruiting
NCT03289039 Phase II Neratinib Fulvestrant + Neratinib Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Active, not recruiting
NCT01912963 Phase II Eribulin Pertuzumab Trastuzumab Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Terminated
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Recruiting
NCT03674112 Phase II Pertuzumab + Trastuzumab A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Active, not recruiting
NCT04351230 Phase II Abemaciclib + Ado-trastuzumab emtansine Ado-trastuzumab emtansine Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer Not yet recruiting
NCT04450732 Phase I GQ1001 Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Recruiting
NCT01148849 Phase I Margetuximab Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT02073487 Phase II Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Completed
NCT02751528 Phase I ETBX-021 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer Active, not recruiting
NCT02789657 Phase II Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Active, not recruiting
NCT03696030 Phase I HER2 CAR-T cells HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Recruiting
NCT04509596 Phase I DZD1516 + Trastuzumab Capecitabine + DZD1516 Ado-trastuzumab emtansine + DZD1516 Capecitabine + DZD1516 + Trastuzumab DZD1516 DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer Not yet recruiting
NCT02595905 Phase II Cisplatin Cisplatin + Veliparib Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Active, not recruiting
NCT03846583 Phase I Abemaciclib + Trastuzumab + Tucatinib Tucatinib + Abemaciclib + Herceptin for HER2+ MBC Not yet recruiting
NCT01622868 Phase II Lapatinib Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Active, not recruiting
NCT01924351 Phase II HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) Withdrawn
NCT03364348 Phase I Trastuzumab + Utomilumab Ado-trastuzumab emtansine + Utomilumab 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Recruiting
NCT04379596 Phase II Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03) Recruiting
NCT01973309 Phase I Paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer Completed
NCT04329065 Phase II Paclitaxel + Pertuzumab + pUMVC3-IGFBP2-HER2-IGF1R vaccine + Trastuzumab Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer Not yet recruiting
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting
NCT04460456 Phase I SBT6050 A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors Recruiting
NCT03529110 Phase III Trastuzumab deruxtecan Ado-trastuzumab emtansine DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] Active, not recruiting
NCT03125928 Phase II Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer Recruiting
NCT04147819 Phase I BAY2701439 A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein Recruiting
NCT01808573 Phase III Capecitabine + Lapatinib Capecitabine + Neratinib A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA) Completed
NCT02189174 Phase Ib/II CLR457 Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Terminated
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Active, not recruiting
NCT03630809 Phase II HER2-pulsed DC1 vaccine Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 Recruiting
NCT04298918 Phase Ib/II Ado-trastuzumab emtansine + Venetoclax Ado-trastuzumab emtansine A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer Recruiting
NCT03501979 Phase II Capecitabine + Trastuzumab + Tucatinib Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD Recruiting
NCT03387553 Phase I HER2-pulsed DC1 vaccine HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Recruiting
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed
NCT03765983 Phase II GDC-0084 + Trastuzumab GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases Recruiting
NCT01160211 Phase III Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Active, not recruiting
NCT02139358 Phase Ib/II Gemcitabine + Pertuzumab + Trastuzumab Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT04108858 Phase Ib/II Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Recruiting
NCT03523572 Phase I Nivolumab + Trastuzumab deruxtecan Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT04294225 Phase II Anastrozole + Letrozole Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Recruiting
NCT02650752 Phase I Capecitabine + Lapatinib Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Active, not recruiting
NCT01875666 Phase I Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Completed
NCT01730833 Phase II Paclitaxel + Pertuzumab + Trastuzumab Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting
NCT04134884 Phase I ASTX727 + Talazoparib Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Recruiting
NCT04042701 Phase I Pembrolizumab + Trastuzumab deruxtecan DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Recruiting
NCT02073916 Phase I Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Completed
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Recruiting
NCT03929666 Phase II Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Leucovorin + ZW25 Capecitabine + Cisplatin + ZW25 A Safety and Efficacy Study of ZW25 Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma Recruiting
NCT04512261 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Women With HER2-Positive Breast Cancer Brain Metastases (TOPAZ) Not yet recruiting
NCT02623972 Phase II Cyclophosphamide + Doxorubicin + Eribulin A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Recruiting
NCT03804515 Phase I Poziotinib A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib Active, not recruiting
NCT01275677 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Docetaxel Cyclophosphamide + Docetaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT03429101 Phase I Ado-trastuzumab emtansine + Poziotinib A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer Terminated
NCT01983501 Phase I Ado-trastuzumab emtansine + Tucatinib A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Completed
NCT01118975 Phase Ib/II Lapatinib + Vorinostat GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers Terminated
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT01596751 Phase Ib/II Eribulin Pexidartinib Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Completed
NCT04539938 Phase II Trastuzumab deruxtecan + Tucatinib A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) Recruiting
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting
NCT02187744 Phase III Carboplatin + Docetaxel + Trastuzumab A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) Completed
NCT04120246 Phase I alpha-TEA + Trastuzumab Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer Recruiting
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Recruiting
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT02152943 Phase I Everolimus + Letrozole + Trastuzumab Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Active, not recruiting
NCT04481113 Phase I Abemaciclib + Niraparib Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Not yet recruiting
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Active, not recruiting
NCT04395508 Expanded access Pertuzumab + Trastuzumab An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic Available
NCT03094052 Phase II Neratinib Loperamide Crofelemer Neratinib + Trastuzumab Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Neratinib, With or Without Trastuzumab Recruiting
NCT04296942 Phase I FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + Entinostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + FPV-Brachyury + M7824 + MVA-BN-Brachyury BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Not yet recruiting
NCT04215146 Phase II Paclitaxel Avelumab + Paclitaxel + Pelareorep Paclitaxel + Pelareorep A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Recruiting
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed
NCT00796978 Phase II Trastuzumab Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Completed
NCT01934894 Phase II Cabazitaxel + Lapatinib Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases Terminated
NCT01922921 Phase Ib/II HER-2/neu intracellular domain protein + Pertuzumab + Polysaccharide-K + Trastuzumab HER-2/neu intracellular domain protein + Pertuzumab + Trastuzumab Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy Unknown status
NCT04510285 Phase II Pembrolizumab + Trastuzumab Trastuzumab Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors Recruiting
NCT02066532 Phase Ib/II Ruxolitinib + Trastuzumab Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Active, not recruiting
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer Active, not recruiting
NCT02659514 Phase II Poziotinib Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT03530696 Phase II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Palbociclib T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) Recruiting
NCT02063724 Phase I HER2-pulsed DC1 vaccine HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) Active, not recruiting
NCT00651976 Phase I Letrozole Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery Terminated
NCT04430738 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Recruiting
NCT04513665 Phase II ZW25 ZW25 in Women With Endometrial Cancers Recruiting
NCT02060253 Phase I Ganetespib + Paclitaxel + Trastuzumab Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Completed
NCT04224272 Phase II Fulvestrant + Palbociclib + ZW25 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer Recruiting
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Recruiting
NCT00411788 Phase II Sirolimus + Trastuzumab A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer Completed
NCT02038010 Phase I Ado-trastuzumab emtansine + Alpelisib BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx Completed
NCT03414658 Phase II Avelumab + Trastuzumab + Utomilumab + Vinorelbine Avelumab + Trastuzumab + Vinorelbine Avelumab + Trastuzumab + Utomilumab Trastuzumab + Vinorelbine The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Recruiting
NCT03377387 Phase Ib/II Capecitabine + Neratinib Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Recruiting